NDAORALTABLETPriority Review
Approved
Feb 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
PYRIDOSTIGMINE BROMIDE (pyridostigmine bromide) by Medica Corp is inhibitor. First approved in 2003.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pyridostigmine bromide is an oral acetylcholinesterase inhibitor approved in 2003 for treating myasthenia gravis and related neuromuscular conditions. It works by inhibiting the breakdown of acetylcholine, thereby increasing neuromuscular transmission and muscle strength. This is a well-established small molecule with a long safety history.
LOE Approaching
With loss of exclusivity approaching, the brand faces moderate competitive pressure (30 score) and likely declining market share, suggesting a smaller, efficiency-focused team focused on retention and cost management.
Mechanism of Action
inhibitor.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on pyridostigmine bromide offers limited growth trajectory given its mature lifecycle stage and approaching loss of exclusivity; however, it provides opportunity to develop expertise in lifecycle management, generic defense strategies, and cost optimization in a stable, well-understood therapeutic area. Professionals joining this product should expect focus on defending market share, managing decline, and transitioning to post-LOE commercial models.
Brand ManagerProduct Manager
Worked on PYRIDOSTIGMINE BROMIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.